Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities
- 70 Downloads
Combined oral contraceptive (COC) treatment has been shown to be associated with glucose deregulation and increased triglyceride levels, but the mechanisms are elusive. Soluble dipeptidyl peptidase-4 (sDPP-4) and adenosine deaminase (ADA) are involved in the initiation and/or progression of cardiometabolic disorders. We therefore, hypothesized that increased DPP-4 and ADA activities are involved in glucose deregulation and hepatic triglyceride accumulation induced by COC treatment. This study also investigated whether short-chain fatty acid, acetate, would protect against COC-induced dysmetabolic effects. Female Wistar rats received (p.o.) vehicle and COC (1.0 μg ethinylestradiol plus 5.0 μg levonorgestrel) with or without sodium acetate (ACE; 200 mg) for 8 weeks. Treatment with COC led to increased plasma triglyceride-glucose index, 1-h postload glucose response, insulin, free fatty acid, insulin resistance, and impaired glucose tolerance. COC treatment also resulted in increased plasma and hepatic triglycerides (TG), TG/HDL-cholesterol ratio, malondialdehyde, uric acid, lactate dehydrogenase, DPP-4, ADA, and xanthine oxidase (XO) activities. On the other hand, COC led to reduction in nitric oxide level. However, ACE significantly ameliorated the alterations induced by COC treatment, but XO activity remains elevated during COC treatment. This result also demonstrates that increased DPP-4 and ADA activities are at least in part involved in glucose deregulation and hepatic TG accumulation induced by COC treatment. Therefore, sodium acetate would impact positively on cardiometabolic disorders, at least in part, by inhibition of DPP-4 and ADA activities.
KeywordsAdenosine deaminase Combined oral contraceptive Dipeptidyl peptidase-4 Hepatic insulin resistance
This research was done without specific grant from any funding agencies in the public, commercial or not-for-profit sectors. The authors appreciate the technical support from the HOPE Cardiometabolic Research Team, Ilorin, Nigeria.
Author contribution statement
OLA conceived and designed the research. OTE conducted experiments. OLA contributed new reagents and analytical kits. OTE, MOS and OLA analyzed and interpreted data. OLA, OTE and MOS drafted the manuscript. OTE, MOS, and OLA read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen AM, Vehkavaara S, Caslake MJ, Packard C, Olofsson SO, Yki-Järvinen H, Taskinen MR, Borén J (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50:2356–2365CrossRefGoogle Scholar
- Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G (2007) Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 6:242–250Google Scholar
- Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, del Prato S, GENFIEV Investigators (2013) Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. J Clin Endocrinol Metab 98:2100–2105CrossRefGoogle Scholar
- Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278(13):11312–11319CrossRefGoogle Scholar
- Fonseca VA (2010) Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. Clin Cornerstone 8:S7–S18Google Scholar
- Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, Anastasovska J, Ghourab S, Hankir M, Zhang S, Carling D, Swann JR, Gibson G, Viardot A, Morrison D, Louise Thomas E, Bell JD (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 5:3611CrossRefGoogle Scholar
- Fuller M, Priyadarshini M, Gibbons SM, Angueira AR, Brodsky M, Hayes MG, Kovatcheva-Datchary P, Bäckhed F, Gilbert JA, Lowe WL Jr, Layden BT (2015) The short-chain fatty acid receptor, FFA2, contributes to gestational glucose homeostasis. Am J Physiol Endocrinol Metab 309:E840–E851CrossRefGoogle Scholar
- Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO et al (2010) The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic hyperinsulinemic clamp. J Clin Endocrinol Metab 95:3347–3351CrossRefGoogle Scholar
- Kurtul N, Pence S, Akarsu E, Kocoglu H, Aksoy Y, Aksoy H (2004) Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Med (Hradec Kralove) 47:33–35Google Scholar
- Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Muller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J (2011) Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60: 1917–1925Google Scholar
- Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585–618Google Scholar
- Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K et al (2012) Increased hepatic expression of dipeptidyl peptidase-4 in nonalcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 5:729–733Google Scholar
- Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, Mori K, Matsunaga Y, Fukushima T, Kanaoka R, Yamamotoya T, Kamata H, Asano T (2015) The xanthine oxidase inhibitor febuxostat suppresses development of non alcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol 309:G42–G51CrossRefGoogle Scholar
- Sell H, Bluher M, Kloting N, Schlich R, Willems M, Ruppe F, Knoefel WT, Dietrich A, Fielding BA, Arner P, Frayn KN, Eckel J (2013) Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36:4083–4090CrossRefGoogle Scholar
- Soha SE, Khaled A, Amani AE (2014) Comparing the effects of inorganic nitrate and allopurinol in renovascular complications of metabolic syndrome in rats: role of nitric oxide and uric acid complications of metabolic syndrome role of nitric oxide and uric acid. Arch Med Sci 10:537–545Google Scholar
- Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Brooks B et al (2015) Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: a dual cohort cross-sectional study. J Diabetes 7(6):809–819CrossRefGoogle Scholar
- Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K (2006) The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116:1913–1923CrossRefGoogle Scholar